Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Test Your Knowledge Previous | All Articles This Week | Next
This article originally posted 13 April, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 621

SPECIAL GLP-1 Test Your Knowledge Question #621

Hayley is a 45 year old female who has been diagnosed with type 2 diabetes mellitus for 2 years....

Advertisement

Her glycosylated hemoglobin (A1c) level is currently 7.9% with a regimen consisting of metformin 1000 mg twice daily, titrated from 500 mg twice daily 1 year ago at which time her A1c was 7.8%. Patient reports good adherence to both her drug regimen and recommended lifestyle modifications. Both you and Hayley are worried about weight gain as she has gained 9 kg since diagnosis, despite her best efforts. You decide to initiate a glucagon like peptide-1 (GLP-1) receptor agonist in addition to metformin.

Which are the main mechanisms of action of glucagon like peptide-1 (GLP-1) receptor agonists?

1.      Inhibits dipeptidyl peptidase-4

2.      Suppresses glucagon secretion

3.      Slows gastric emptying

4.      Blocks sodium glucose transporter in proximal tubule

5.      Increases secretion of insulin in the presence of elevated glucose

Please choose one answer:

a.    1 and 3

b.    2, 3 and 5

c.    2 and 4

d.    3, 4 and 5 

For the correct answer, please click here.

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 13 April, 2012 and appeared in  GLP-1 Receptor Agonist TherapyIssue 621

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
Diabetes Epidemic Growing
Posted May 23, 2013
Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013
Pros and Cons of Incretin-Based Therapies
Posted May 30, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control



Search Articles On Diabetes In Control